OD06 - Gout in Chronic Kidney Disease/End-Stage Kidney Disease: Where Are We Today?

This session explores the impact and relationship of gout in the presence of kidney disease. New treatment therapies along with pharmacologic and non-pharmacologic options are discussed.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 5/10/2025.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:
Christine Corbett, DNP, FNP-BC, CNN-NP, FNKF – Consultant/Speakers Bureau for GSK Anemia.
Leah Foster Smith, MSN, APRN, FNP-BC, CNN-NP, FNKF – Owner and Chief Education Officer for Interactive Nephrology

There are no other Planning Committee disclosures to declare.

Speaker Disclosures:
Trenton Gray: Consultant, Horizon Therapeutics

There are no other speaker disclosures to declare.

Commercial Support:
No commercial support declared.

Accreditation Statement:
The American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.

ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this learning activity, the participant will state an increased knowledge base of gout in CKD patients related to assessment, pathophysiology, along with planning and providing nursing care.